William Hwang
Principal Investigator
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (10)
Purpose: Pancreatic ductal adenocarcinoma (PDAC) cells exist on a spectrum of epithelial (E) and quasi-mesenchymal (QM) transcriptional states, with differences in sensitivity to FOLFIRINOX (FFX). Glycogen synthase kinase 3β (GSK-3β) is a key regulator of PDAC cell epithelial-to-mesenchymal transition (EMT). Patients and Methods: In vitro analysis of PDAC cell lines combined with multiomic analysis of data from a GSK-3β inhibitor trial (NCT05077800) was conducted to evaluate treatment effects on EMT. Results: GSK-3β inhibition with elraglusib (ELRA) drives QM PDAC cells toward an E state, demarcated by decreased transcription of QM genes FN1 and TGFB1 and an induction of E genes KRT8 and CEACAM6. A comparison of differentially expressed genes (DEG) in PDAC cell lines with tumors from patients with PDAC treated in a safety cohort combining FFX, ELRA, and losartan demonstrated 97 overlapping DEGs with concordant directional changes. ELRA treatment consistently suppressed EMT pathway expression. The synergy of ELRA with cytotoxic doses of FFX in 3D culture was observed only in QM PDAC lines. The FFX/ELRA combination demonstrated initial evidence of clinical benefit, with three of six patients experiencing a partial response (PR) for a duration of at least 20 months. Interestingly, PRs were observed in patients with tumors demonstrating a baseline high proportion of QM cells that transitioned to E predominant tumors with ELRA treatment. Lastly, the influx of M1 tumor-associated macrophages, CD4/CD8 lymphocytes, and NK cells was observed with ELRA clinical response using a combination of GeoMx, snRNA-seq, and ferumoxytol-enhanced MRI. Conclusions: GSK-3β blockade synergizes with FFX by modulating PDAC plasticity while promoting the development of a tumor-suppressive immune microenvironment.
Year:
2026
Analyses of patient-derived cell lines have greatly enhanced discovery of molecular biomarkers and therapeutic targets. However, characterization of cellular morphological properties is limited. We studied cell morphologies of human pancreatic adenocarcinoma (PDAC) cell lines and their associations with drug sensitivity, gene expression, and functional properties. By integrating live cell and spatial messenger RNA imaging, we identified KRAS inhibitor–induced morphological changes specific for drug-resistant cells that correlated with gene expression changes. We then categorized a large panel of patient-derived PDAC cell lines into morphological and organizational subtypes and found differences in gene expression, therapeutic targeting potential, and metastatic proclivity. Patterns of cancer cell organization in human PDAC tissues stratified distinct gene expression signatures with clinical significance. In summary, we highlight the potential of cell morphological information in rapid, cost-effective assays to aid precision oncology efforts leveraging patient-derived in vitro models and tissues.
Year:
2025
Co-occupied and unique target genes shared between Creb and RNApol-II in chromatin immunoprecipitation and sequencing (ChIP-seq) experiments performed in murine Kras-Trp53 cooperative KPC pancreatic cancer cells
Year:
2025
We have shown that KRAS–TP53 genomic coalteration is associated with immune-excluded microenvironments, chemoresistance, and poor survival in pancreatic ductal adenocarcinoma (PDAC) patients. By treating KRAS – TP53 cooperativity as a model for high-risk biology, we now identify cell-autonomous Cxcl1 as a key mediator of spatial T-cell restriction via interactions with CXCR2 + neutrophilic myeloid-derived suppressor cells in human PDAC using imaging mass cytometry. Silencing of cell-intrinsic Cxcl1 in LSL-Kras G12D/+ ;Trp53 R172H/+ ;Pdx-1 Cre/+ (KPC) cells reprograms the trafficking and functional dynamics of neutrophils to overcome T-cell exclusion and controls tumor growth in a T cell–dependent manner. Mechanistically, neutrophil-derived TNF is a central regulator of this immunologic rewiring, instigating feed-forward Cxcl1 overproduction from tumor cells and cancer-associated fibroblasts (CAF), T-cell dysfunction, and inflammatory CAF polarization via transmembrane TNF–TNFR2 interactions. TNFR2 inhibition disrupts this circuitry and improves sensitivity to chemotherapy in vivo . Our results uncover cancer cell–neutrophil cross-talk in which context-dependent TNF signaling amplifies stromal inflammation and immune tolerance to promote therapeutic resistance in PDAC. Significance: By decoding connections between high-risk tumor genotypes, cell-autonomous inflammatory programs, and myeloid-enriched/T cell–excluded contexts, we identify a novel role for neutrophil-derived TNF in sustaining immunosuppression and stromal inflammation in pancreatic tumor microenvironments. This work offers a conceptual framework by which targeting context-dependent TNF signaling may overcome hallmarks of chemoresistance in pancreatic cancer. This article is highlighted in the In This Issue feature, p. 1275
Year:
2025
Year:
2024
Clinical treatment of cancer commonly incorporates X‐ray radiation therapy (XRT), and developing spatially precise radiation‐activatable drug delivery strategies may improve XRT efficacy while limiting off‐target toxicities associated with systemically administered drugs. Nevertheless, achieving this has been challenging thus far because strategies typically rely on radical species with short lifespans, and the inherent nature of hypoxic and acidic tumor microenvironments may encourage spatially heterogeneous effects. It is hypothesized that the challenge could be bypassed by using scintillating nanoparticles that emit light upon X‐ray absorption, locally forming therapeutic drug depots in tumor tissues. Thus a nanoparticle platform ( Sci ntillating nanoparticle D rug D epot; SciDD) that enables the local release of cytotoxic payloads only after activation by XRT is developed, thereby limiting off‐target toxicity. As a proof‐of‐principle, SciDD is used to deliver a microtubule‐destabilizing payload MMAE (monomethyl auristatin E). With as little as a 2 Gy local irradiation to tumors, MMAE payloads are released effectively to kill tumor cells. XRT‐mediated drug release is demonstrated in multiple mouse cancer models and showed efficacy over XRT alone ( p < 0.0001). This work shows that SciDD can act as a local drug depot with spatiotemporally controlled release of cancer therapeutics.
Year:
2024
Co-occupied and unique target genes shared between Creb and RNApol-II in chromatin immunoprecipitation and sequencing (ChIP-seq) experiments performed in murine Kras-Trp53 cooperative KPC pancreatic cancer cells
Year:
2024
Co-occupied and unique target genes shared between Creb and RNApol-II in chromatin immunoprecipitation and sequencing (ChIP-seq) experiments performed in murine Kras-Trp53 cooperative KPC pancreatic cancer cells
Year:
2024
Year:
2023
Year:
2023
Collaborators (14)
Ben Stanger
University of Pennsylvania
Nipun B. Merchant
University of Miami Miller School of Medicine
Mukesh Harisinghani
Harvard University
Elizabeth Montgomery
Professor of Pathology
University of Miami Hospital
Jashodeep Datta
University of Miami
Roberta Brambilla
Assistant Professor
University of Miami School of Medicine
Ralph Weissleder
Harvard University
Eneda Toska
Associate Professor
NYU School of Medicine
Kathleen DelGiorno
Assistant Professor
Vanderbilt University
Alejandro Villarino
Assistant Professor
University of Miami
David Ting
Associate Professor of Medicine
-
Colin Weekes
Associate Professor
Massachusetts General Hospital
Nagaraj S. Nagathihalli
Associate Professor with Tenure
University of Miami
Mingjuan Zhang
Faculty
Massachusetts General Hospital
Make your next move.
Prepare your application
Review drafts before you send them.